COVID Vaccine Transition Planning: Price Does Not Come Up At ACIP
Executive Summary
US CDC is starting to prepare for the transition of COVID vaccine deliver to more traditional commercial channels. It is noteworthy that the first discussion of what will change did not include any talk of prices.
You may also be interested in...
US CDC Leadership Transition Set; Timing Sidesteps Potential Rx Pricing Debate
President Biden has selected a new director for the US Centers for Disease Control and Prevention, and the pick – former CMS official Mandy Cohen – is likely to be the last who is not subject to confirmation in the Senate. That is an important nuance in the current political climate for drug pricing policies.
BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes
Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.
BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes
Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.